Treatment Experience and Repeat Pregnancy Impact the Effectiveness of Non-Nucleoside Reverse Transcription Inhibitor-Highly Active Antiretroviral Therapy for the Prevention of Mother to Child Transmission of Human Immunodeficiency Virus
Restricted accessResearch articleFirst published online August, 2020
Treatment Experience and Repeat Pregnancy Impact the Effectiveness of Non-Nucleoside Reverse Transcription Inhibitor-Highly Active Antiretroviral Therapy for the Prevention of Mother to Child Transmission of Human Immunodeficiency Virus
Non-nucleoside reverse transcription inhibitor (NNRTI)-containing antiretroviral therapy (ART) for the prevention of mother to child transmission (PMTCT) of human immunodeficiency virus (HIV) has led to dramatic reductions in perinatal HIV infection in resource-constrained settings. Nonetheless, PMTCT programs are complicated by repeat pregnancies, in which long-term or repeat exposures to PMTCT regimens over time may lead to the acquisition of HIV drug resistance mutations, and consequent treatment failure. In this study, we retrospectively assessed the effectiveness of the NNRTI-based PMTCT protocol from 2008 to 2010 in The Bahamas National HIV/AIDS Program. We show that women who had been in repeat pregnancies and those who were already prescribed ART at conception were at increased risk of virologic failure, relative to treatment-inexperienced women and primigravida, respectively (AOR 3.1, 95% CI: 1.3–7.1, p = .008 and AOR 5.0, 95% CI: 1.8–14.1, p = .002). In addition, women undergoing treatment at conception were more likely to possess HIVDR mutations relative to treatment-naive women (AOR 447.1, 95% CI: 17.9–11,173.5, p = .001). Therefore, individual treatment history is a key metric determining the effectiveness of current and future PMTCT interventions. The implications of this to PMTCT programmatic success in light of the most recent WHO guidelines are discussed.
Get full access to this article
View all access options for this article.
References
1.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach- Second edition. Geneva, Switzerland: World Health Organization, 2016.
2.
World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization, 2019.
3.
World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection infants. Recommendations for a public health approach. Geneva, Switzerland: World Health Organization, 2010.
4.
ParedesR, MarconiVC, LockmanS, et al.: Impact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes. J Infect Dis, 2013; 207 (Suppl 2):S93–S100.
5.
Palella JrF, ChmielJ, MoormanA, HolmbergS: Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV infected patients. HIV Outpatient Study Investigators. AIDS, 2002; 1612:1617–1626.
6.
CuzinL, PuglieseP, BugnonF, et al.: Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: Efficacy and durability in a prospective cohort of French HIV-infected patients. HIV Med, 2005; 6:388–395.
7.
UngsedhapandC, SrasuebkulP, CardielloP, et al.; HIV-NAT 002 and HI, V-NAT 003 Study Team: Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. J Acquir Immune Defic Syndr, 2004; 36:693–701.
8.
BenatorDA, ElmiA, RodriguezMD, et al.: True durability: HIV virologic suppression in an urban clinic and implications for timing of intensive adherence efforts and viral load monitoring. AIDS Behav, 2015; 19:594–600.
9.
DesmondeS, EbouaFT, MalatesteK, et al.; IeDEA Pediatric West African Working Group: Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation. AIDS, 2015; 29:1527–1536.
10.
ShethAN, OfotokunI, BuchaczK, et al.: Antiretroviral Regimen Durability and Success in Treatment-Naive and Treatment-Experienced Patients by Year of Treatment Initiation, United States, 1996–2011. J Acquir Immune Defic Syndr, 2016; 71:47–56.
11.
XingH, RuanY, LiJ, et al.: HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients. Chinese National HIVDR Surveillance and Monitoring Network. PLoS One, 2013; 8:e54917.
12.
BilliouxA, NakigoziG, NewellK, et al.: Durable Suppression of HIV-1 after Virologic Monitoring-Based Antiretroviral Adherence Counseling in Rakai, Uganda. PLoS One, 2015; 10:e0127235.
13.
FloridiaM, TamburriniE, MasuelliG, et al.: Rate, correlates and outcomes of repeat pregnancy in HIV-infected women. Italian Group for Surveillance of Antiretroviral Treatment in Pregnancy. HIV Med, 2017; 18:440–443.
14.
FrenchCE, Cortina-BorjaM, ThorneC, TookeyPA: Incidence, patterns, and predictors of repeat pregnancies among HIV-infected women in the United Kingdom and Ireland, 1990–2009. J Acquir Immune Defic Syndr, 2012; 59:287–293.
15.
KreitchmannR, MegazziniK, MeloVH, et al.: Repeat pregnancy in women with HIV infection in Latin America and the Caribbean. AIDS Care, 2015; 27:1289–1297.
16.
WattsDH, HuangS, CohnSE, SmithL, HittiJ: Repeat pregnancies among HIV-infected women enrolled in clinical trial PACTG1022. J Acquir Immune Defic Syndr, 2009; 51:231–233.
17.
AkeloV, McLellan-LemalE, ToledoL, et al.: Determinants and Experiences of Repeat Pregnancy among HIV-Positive Kenyan Women—A Mixed-Methods Analysis. PLoS One, 2015; 10:e0131163.
18.
SuryavanshiN, ErandeA, PisalH, et al.: Repeated pregnancy among women with known HIV status in Pune, India. AIDS Care, 2008; 20:1111–1118.
19.
FrenchCE, TookeyPA, Cortina-BorjaM, de RuiterA, TownsendCL, ThorneC: Influence of short-course antenatal antiretroviral therapy on viral load and mother-to-child transmission in subsequent pregnancies among HIV-infected women. Antivir Ther, 2013; 18:183–192.
20.
FrenchCE, ThorneC, TariqS, Cortina-BorjaM, TookeyPA: Immunologic status and virologic outcomes in repeat pregnancies to HIV-positive women not on antiretroviral therapy at conception: A case for lifelong antiretroviral therapy?. AIDS, 2014; 28:1369–1372.
21.
GerettiAM, FoxZ, JohnsonJA, et al.; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group: Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. PLoS One, 2013; 8:e69266.
22.
LyonsFE, CoughlanS, ByrneCM, HopkinsSM, HallWW, MulcahyFM: Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS, 2005; 19:63–67. Erratum in: AIDS 2007 21:1671.
23.
ParedesR, ChengI, KuritzkesDR, Tuomala RE; Women and Infants Transmission Study (WITS) Group: Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS, 2010; 24:45–53.
24.
EllisGM, HuangS, HittiJ, FrenkelLM; P1022 Study Team: Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. J Acquir Immune Defic Syndr, 2011; 58:241–247.
25.
DuranAS, LossoMH, SalomónH, et al.; NISDI Perinatal Study Group: Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis. AIDS, 2007; 21:199–205.
26.
PérezH, VignolesM, LauferN, et al.: Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen. Antivir Ther, 2008; 13:135–139.
27.
Soto-RamirezLE, Rodriguez-DiazR, DuránAS, et al.; NISDI Perinatal Study Group: Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: Plasma versus PBMCs. AIDS Res Hum Retroviruses, 2008; 24:797–804.
28.
HarriganPR, HoggRS, DongWW, et al.: Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis, 2005; 191:339–347.
29.
RupérezM, Noguera-JulianM, GonzálezR, et al.HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique. PLoS One, 2018; 13:e0196451.
30.
AdeniyiOV, ObiC, GoonD, et al.: HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: Implications for elimination of mother-to-child transmission. J Clin Virol, 2019; 117:89–95.
31.
MilneR, SilvermanR, BeckI, et al.: Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women. AIDS, 2019; 33:941–951.
32.
Martin-OdoomA, BrownC, OdoomK, et al.: Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana. Virol J, 2018; 15:143.
33.
TamLW, ChuiCK, BrummeCJ, et al.: The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes., J Acquir Immune Defic Syndr, 2008; 49:266–271.
34.
WilsonIB, BangsbergDR, ShenJ, et al.; Multisite Adherence Collaboration on HIV 14 Investigators: Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: Results from the multisite adherence collaboration on HIV 14 study. J Acquir Immune Defic Syndr, 2013; 64:448–454.
35.
MeresseM, MarchL, KouanfackC, et al.; Stratall ANRS 12110/ESTHER Study Group: Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon. HIV Med, 2014; 15:478–487.
36.
LiJZ, ParedesR, RibaudoHJ, et al.: Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS, 2012; 26:185–192.
37.
HosseinipourM, NelsonJAE, TrapenceC, et al.; PURE Malawi Consortium: Viral Suppression and HIV Drug Resistance at 6 Months Among Women in Malawi's Option B+ Program: Results From the PURE Malawi Study. J Acquir Immune Defic Syndr, 2017; 75(Suppl 2):S149–S155.
38.
MachnowskaP, HauserA, MeixenbergerK, et al.: Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT. PLoS One, 2017; 12:e0178297.
39.
GillMM, HoffmanHJ, BobrowEA, et al.: Detectable Viral Load in Late Pregnancy among Women in the Rwanda Option B+ PMTCT Program: Enrollment Results from the Kabeho Study. PLoS One, 2016; 11:e0168671.
40.
NgarinaM, KilewoC, KarlssonK, et al.: Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania. BMC Infect Dis, 2015; 15:175.
41.
HaasAD, MsukwaMT, EggerM, et al.: Adherence to Antiretroviral Therapy During and After Pregnancy: Cohort Study on Women Receiving Care in Malawi's Option B+ Program. Clin Infect Dis, 2016; 63:1227–1235.
42.
TesfayeDJ, HibistuDT, AbeboTA, et al.: Option B plus antiretroviral therapy adherence and associated factors among HIV positive pregnant women in Southern Ethiopia. BMC Pregnancy Childbirth, 2019; 19:82.
43.
GallowayD.“African Tradition, Proverbs, and Sankofa”, The Spirituals Project at the University of Denver. Available at https://web.archive.org/web/20110423095008/http://ctl.du.edu/spirituals/literature/index.cfm (2004), accessed Jan,2020.
44.
Dorward DorwardJ, LessellsR, DrainPK, et al.: Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: Uncertainties and opportunities for implementation and research. Lancet HIV, 2018; 5:e400–e404.
45.
DemarestJ, UnderwoodM, St ClairM, DoreyD, BrownD, ZolopaA: Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance. AIDS Res Hum Retroviruses, 2018; 34:343–346.
